Current Perspectives in Haematological Malignancies

Illidge, T. (Chair)

Division of Cancer Sciences (L5)

Activity: Participating in or organising event(s) › Participating in a conference, workshop, exhibition, performance, inquiry, course etc › Research

Description

GALLIUM : Obinutuzumab, not rituximab, should be used first line for patients with symptomatic follicular lymphoma
Chair: Professor Tim Illidge, Manchester

Period	10 Oct 2018
Event type	Conference

Research Beacons, Institutes and Platforms

Lydia Becker Institute